 |
|
|
| |
High Rate of Sustained Virologic Response With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor), With or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With HCV GT 1, 2, or 3
|
| |
| |
Reported by Jules Levin
AASLD
Nov 9-13 2012 Boston
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Eley T, Wind-Rotolo M, Huang S-P, Gao M,McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, andGrasela DM for the AI444040 Study Group
|
| |
|
|
|
|
|
